Icosagen In The News

Icosagen Cell Factory is looking for a Sales Manager

A vacancy for a Manager of Scientific Sales in the direction of providing licensing and services for a new technology platform is available in Icosagen Cell Factory.
Proceed »

New QMCF Technology application: generation of Cell based translocation assays has been launched

In December 2011 Icosagen Cell Factory completed a two-years applied research project to use QMCF Technology for screening of target proteins in cell based assays for signal pathway studies and high-content screening applications.

Proceed »

QMCF Technology to present at the 7th annual European Antibody Congress

On November, 30th 2011, Professor Mart Ustav, CEO of Icosagen Cell Factory will introduce QMCF Technology for antibody production at the 7th annual European Antibody Congress in Geneva (CH).
Proceed »

QMCF Technology to present at the IBC's 8th annual Early Development Forum

On September, 13th 2011 Dr Andres Tover, CSO of Icosagen Cell Factory, will introduce QMCF Technology for production of proteins, antibodies and virus-like particles; and for generation of cell based translocation assays. The talk will be held during the IBC's 8th Annual Early Development Forum in the stream of Preclinical Scale Bioprocessing in San Diego.
Proceed »

Icosagen Cell Factory to present at the 7th annual PEGS Summit in Boston

During the 7^th PEGS Summit in Boston, Professor and CEO of Icosagen Cell Factory Mart Ustav will have a talk about QMCF Technology and its applications.
Proceed »

QMCF Technology has been licensed to GSK Biologicals for evaluation

Icosagen Cell Factory announced today it has signed an agreement for GlaxoSmithKline Biologicals (GSK Biologicals) to evaluate the QMCF Technology with an option, if successful, to proceed with a license to use the Technology for research activities.

Proceed »

Prolonged contract with Swedish Orphan Biovitrum

Icosagen Cell Factory OÜ and Swedish Orphan Biovitrum AB (SOBI) prolonged an agreement pursuant to which a technology licence to SOBI was granted to evaluate the QMCF Technology with the option to proceed with a license to use the Technology for research activities.

Proceed »

PRESENTATION ABOUT QMCF TECHNOLOGY AT THE 4TH PROTEIN CONGRESS

During the 4^th Protein and Vaccines Congress in London, Professor and CEO of Icosagen Cell Factory Mart Ustav will have a talk “Fast, simple and efficient method for production of biologics using stable episomal expression system – QMCF Technology”.

Proceed »

QMCF Technology presentation at the European Antibody Congress

Professor and CEO of Icosagen Cell Factory Mart Ustav will have a talk “QMCF Technology for protein expression and construction of cell-based assays” at the European Antibody Congress in  November 30 2010 in Geneva.  Proceed »

A UNITED STATES PATENT HAS BEEN GRANTED TO THE QMCF TECHNOLOGY

The United States Patent and Trademark Office granted on 07 September 2010 a Patent No US 7790446 B2 with the title “Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products” to Icosagen Cell Factory that is related to the QMCF Technology.

Proceed »

Icosagen Cell Factory will have a talk at the MipTec Conference

Professor and CEO of Icosagen Cell Factory Mart Ustav will have a talk “Development of the extrachromosomal expression system for production of therapeutic proteins and for cell-based assays” on September 20, 2010.

Proceed »

Icosagen Cell Factory signed a contract with Sanofi Pasteur

Icosagen Cell Factory OÜ and Sanofi Pasteur, the vaccines division of sanofi-aventis Group, signed an agreement pursuant to which a technology licence to Sanofi Pasteur was granted to evaluate the QMCF technology with the option to proceed with a license for research activities.

Proceed »

Icosagen Cell Factory granted a license to Bayer HealthCare

Icosagen Cell Factory OÜ and Bayer HealthCare extended an existing agreement, pursuant to which a non-exclusive licence to use QMCF technology for research activities was granted to Bayer HealthCare. Proceed »

Enterprise Estonia issued a grant to Icosagen Cell Factory

Icosagen Cell Factory has received an applied reseach grant from Enterprise Estonia to develop a technology for cell-based assay construction that utilises elements from QMCF Technology proprietary to the company. The reseach grant is MEUR 1. The total amount of the R&D project is MEUR 1.5. The project starts on 1 September and lasts for a period of two years.

Proceed »

Icosagen Cell Factory has been granted a European patent

Proceed »

Icosagen Group has a new homepage

As of 9 April 2009, the Icosagen Group has a new homepage at the address www.icosagen.ee

Proceed »

The new business name of Quattromed Group is Icosagen Group

On 02 March 2009, the new business names of AS Quattromed and OÜ Quattromed Cell Factory were registered. The new business name of Quattromed AS is Icosagen AS, and the new business name of subsidiary Quattromed Cell Factory OÜ is Icosagen Cell Factory OÜ. Proceed »

Quattromed Cell Factory signed a contract with Bayer HealthCare

Quattromed Cell Factory announced the signing of an agreement with Bayer HealthCare, pursuant to which Quattromed Cell Factory granted a licence to Bayer HealthCare to test novel QMCF technology with the option to proceed with a technology license Proceed »

FITkit® technology has become an international standard

ASTM International (www.astm.org) adopted a new standard "Standard Test Method for Immunological Measurement of Four Principal Allergenic Proteins in Natural Rubber and Products Derived from Latex" that bases that bases on Icosagen’s FITk® technology. Proceed »

The US patent for Protease Pro 39

On 13 March 2007, The United States Patent and Trademark Office issued patent No US7189540  Proceed »